Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;12(8):1256-1261.
doi: 10.4103/1673-5374.213541.

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy

Asha Hiremathad  1 , Luca Piemontese  2
Affiliations
Review

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy

Asha Hiremathad et al. Neural Regen Res. 2017 Aug.

Abstract

Nowadays, Alzheimer's disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhibitors, memantine is a N-methyl-D-aspartate receptor antagonist, whereas the fifth formulation is a combination of donepezil with memantine. The prevention and treatment of AD is the new challenge for pharmaceutical industry, as well as for public institutions, physicians, patients, and their families. The discovery of a new and safe way to cure this neurodegenerative disease is urgent and should not be delayed further. Because of the multiple origin of this pathology, a multi-target strategy is currently strongly pursued by researchers. In this review, we have discussed new structures designed to better the activity on the classical AD targets. We have also examined old and new potential drugs that could prove useful future for the therapy of the pathology by acting on innovative, not usual, and not yet fully explored targets like peroxisome proliferator-activated receptor (PPARs).

Keywords: AlzheimerZ's disease; heterocyclic compounds; multi-target strategy; neurodegenerative diseases; peroxisome proliferator-activated receptors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

References

    1. Alzheimer’s Association (2014) Alzheimer’s disease facts and figures. Alzheimers Dement. 10:47–92. - PubMed
    1. Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, da Cunha C, Lucio Boschen S, Lima MM, Vital MA. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine. Behav Brain Res. 2014;274:390–399. - PubMed
    1. Carrieri A, Giudici M, Parente M, De Rosas M, Piemontese L, Fracchiolla G, Laghezza A, Tortorella P, Carbonara G, Lavecchia A, Gilardi F, Crestani M, Loiodice F. Molecular determinants for nuclear receptors selectivity: Chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists. Eur J Med Chem. 2013;63:321–332. - PubMed
    1. Chand K, Alsoghier HM, Chaves S, Santos MA. Tacrine-(hydroxybenzoyl-pyridone) hybrids as potential multifunctional anti-Alzheimer’s agents: AChE inhibition, antioxidant activity and metal chelating capacity. J Inorg Biochem. 2016;163:266–277. - PubMed
    1. Chaves S, Piemontese L, Hirematad A, Santos MA. Hydroxypyridinone derivatives: a fascinating class of chelators with therapeutic applications - an update. Curr Med Chem. 2017 doi: 10.2174/09298673246 66170330092304. - PubMed